Fact CheckerSign in

NCT07616986Recruiting

LITT for Ultra-early GBM Recurrence

Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence

Source: ClinicalTrials.gov · Last updated 1 Jun 2026

Brief summary (registry, in English)

Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy. LITT offers a minimally invasive alternative that may: * Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
12 (estimated)
First submitted
24 Nov 2025
Start date
Feb 2026
Primary completion date
Jul 2027
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Diseases
Glioblastoma
NCT number
NCT07616986

What you commit to

  • Study type: Interventional
  • Planned participants: 12
  • From Feb 2026 to the primary completion date, Jul 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
  • ≥18 years of age
  • CRET
  • Karnofsky Performance Status (KPS) ≥70
  • No contra-indication for radio-chemotherapy
  • Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern
  • Able to provide informed consent
  • No contra-indication for LITT
  • No pregnancy or active breast-feeding
  • No known coagulopathy independent of medication
  • No dissemination or multifocal disease
  • Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Dep. of Neurosurgery, Bern University Hospital
Coordinator of this site? Confirm its status
BernSwitzerlandRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.